CERo Therapeutics Doses Third Patient In Phase 1 AML Trial Of CER-1236

Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort

SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, today announced that it has dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid leukemia (AML). Per protocol, three patients are planned at this lowest dose level, and enrollment of the third subject may complete the initial cohort pending the outcome of protocol-defined safety assessments, including the dose-limiting toxicity (DLT) evaluation period.